Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
- Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
October 08, 2021
- Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering
October 06, 2021
- Xenon Pharmaceuticals Announces Proposed Public Offering
October 04, 2021
- Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
October 04, 2021
Product Pipeline
XEN1101
for Adult Focal Epilepsy
X-TOLE Clinical Trial
XEN1101
for Major Depressive Disorder (MDD)
Investigator-led Phase 2 POC study Collaboration with Mount Sinai
XEN1101
for MDD
Company-sponsored Phase 2 POC study
XEN496
for Orphan Pediatric Epilepsy (KCNQ2-DEE)
EPIK Clinical Trial
XEN007
for Pediatric Absence Epilepsy
Investigator-led Phase 2 POC study Absence Epilepsy
NBI-921352
for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences
NBI-921352
for Focal-Onset Seizures in Adults
Partnered with Neurocrine Biosciences
FX301
for Post-Operative Pain
Partnered with Flexion Therapeutics
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
